Lupin launches generic Niaspan tablets in US market

Mumbai-based pharma major Lupin Ltd today launched its generic version of Niaspan extended release tablets, used in reducing cholesterol in the US market.

The company's US subsidiary, Lupin Pharmaceuticals Inc has launched the generic Niaspan tablets in multiple strengths of 500mg, 750 mg & 1000 mg having received final approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

These tablets are generic equivalent of AbbVie Inc's Niaspan tablets.

Commenting on the launch, Lupin Ltd Managing Director Nilesh Gupta said: "We are happy to launch this product having received approval from the (US) FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market."

Citing IMS MAT data, the company said Niaspan Tablets had annual sales of of approximately USD 1 billion in the US in 2013.

Niaspan tablets are used with diet to lower bad cholesterol while increasing the levels of good cholesterol in the body.

Lupin Ltd shares gained 0.45 per cent on the BSE from the previous close, ending the day at Rs 944.2 per scrip.

EDITORIAL OF THE DAY

  • Public musn’t pay for domestic servants for our diplomats

    Nothing seems to have changed in the year and half since the fur that flew thick and fast over the case of diplomat Debjani Khobragade and her maid Sa

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

Economic integration in east Asia

As trade agreements within a global framework have become increasingly ...

Rajgopal Nidamboor

Up the ante of your conscious existence

It sounds cryptic, but is not as complex as it ...

Gautam Gupta

The ‘fake’ issue needs to be taken seriously

E-commerce players are witnessing unbelievable growth globally. Competition is increasing ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture